Drug resistance in oncology
Author(s)
Bibliographic Information
Drug resistance in oncology
Marcel Dekker, c1993
Available at 7 libraries
Note
Includes bibliographical references and index
Description and Table of Contents
Description
This volume focuses on the mechanisms that involve alterations in cellular biochemistry, properties related to the physiology of the solid tumour mass and changes in the host metabolic status induced by the presence of the tumour - applying this information to the resistance to cancer chemotherapy, radiation therapy and biomodulator therapies. Written by over 25 experts from diverse scientific areas, this book: covers angiogenesis and blood-flow, pH, oxygenation, molecular transport and tissue pressure, oncogenes and tumour-suppressor genes, extracellular matrix and phosphate metabolism; discusses clonal subpopulations, resistance in leukimia, the blood brain barrier, tumour/host interactions and the metastatic phenotype; examines glutathione, metallothionein, glutathione-S-transferases, oxazaphosphorane metabolism, cytochrome P-450, multi-drug resistance and nuclear matrix influence; and presents the effects of antioestrogens, chorionic gonadotropin, transforming and fibroblast growth factors, metastases and radiation resistance.
Table of Contents
- Part 1 Physiological resistance in solid tumours: angiogenesis and blood flow in solid tumours, Mark W. Dewhirst
- intra- and extracellular pH in solid tumours - influence on therapeutic response, Chang W. Song et al
- oxygenation of solid tumours, Peter W. Vaupel
- physiological resistance to the treatment of solid tumours, Rakesh K. Jain
- the role of oncogenes and tumour-suppressor genes in tumour angiogenesis, Lynn C. Yeoman
- the role of extracellular matrix in tumour invasion, metastasis and angiogenesis, Yves A. de Clerck and Walter E. Laug
- prediction of tumour treatment response using magnetic resonance spectroscopy, Paul Okunieff. Part 2 Biological resistance: heterogeneous clonal subpopulations in solid tumours, John T. Leith and Seth Michelson
- tumour subpopulation interactions and the expression of drug resistance, Gloria H. Heppner and Bonnie E. Miller
- therapeutic resistance in leukemia, William R. Waud and Daniel P. Griswold, Jr
- tumour site effects - central nervous system tumours, Henry S. Friedman and S. Clifford Schold, Jr
- in vivo resistance to antitumour alkylating agents, Beverly A. Teicher
- characteristics of the metastatic phenotype, Vincent J. Hearing. Part 3 Biochemical resistance: the role of glutathione and associated enzymes in the cellular response to radiation, peroxide and hydroperoxides, John E. Biaglow and Steve W. Tuttle
- metallothioneins in drug resistance, Nagahiro Saijo and John Stephen Lazo
- glutathione-S-transferases, Paul J. Ciaccio and Kenneth D. Tew
- oxazaphosphorine-specific acquired cellular resistance, Norman E. Sladek
- tumour-cell drug metabolism and drug resistance, Dennis E. Chapman and Garth Powis
- P-glycoprotein mediated multi-drug resistance, Bernard W. Futscher and William S. Dalton
- topoisomerase-related mechanisms of drug resistance, Daniel J. Fernandes et al. Part 4 The role of hormones, growth factors and oncogenes: acquisition of antioestrogen resistance in breast cancer, Robert Clarke and Marc E. Lippman
- chorionic gonadotropin - a tumouristatic and preventive agent in breast cancer, Irma H. Russo and J. Russo
- roles of TGF-B and FGF in tumour progression and metastastis, Danny R. Welch and Motowo Nakajima
- possible contribution of growth factors to the evolution of metastasis and de novo multidrug resistance in cancer, R. Kerbel and John R. MacDougall
- signal transduction and gene expression during mammalian cell response to ionizing radiation, Dennis E. Halllahan et al. Part 5 Clinical aspects of resistance: cancer chemotherapy - clinical evidence for drug resistance, Louis J. Ayash et al.
by "Nielsen BookData"